Follow
David Ridley
Title
Cited by
Cited by
Year
Developing drugs for developing countries
DB Ridley, HG Grabowski, JL Moe
Health Affairs 25 (2), 313-324, 2006
2352006
Entry and competition in generic biologics
HG Grabowski, DB Ridley, KA Schulman
Managerial and Decision Economics 28 (4‐5), 439-451, 2007
862007
Distance decreases with differentiation: Strategic agglomeration by retailers
GA Picone, DB Ridley, PA Zandbergen
International Journal of Industrial Organization 27 (3), 463-473, 2009
772009
Pharmaceutical followers
P Arcidiacono, PB Ellickson, P Landry, DB Ridley
International Journal of Industrial Organization 31 (5), 538-553, 2013
702013
Price differentiation and transparency in the global pharmaceutical marketplace
DB Ridley
Pharmacoeconomics 23 (7), 651-658, 2005
602005
Would greater transparency and uniformity of health care prices benefit poor patients?
MK Kyle, DB Ridley
Health Affairs 26 (5), 1384-1391, 2007
552007
Herding versus Hotelling: Market entry with costly information
DB Ridley
Journal of Economics & Management Strategy 17 (3), 607-631, 2008
452008
The commercial market for priority review vouchers
DB Ridley, SA Régnier
Health Affairs 35 (5), 776-783, 2016
342016
Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases
DB Ridley, AC Sánchez
The Lancet 376 (9744), 922-927, 2010
332010
Impact of Medicaid preferred drug lists on therapeutic adherence
DB Ridley, KJ Axelsen
Pharmacoeconomics 24 (3), 65-78, 2006
292006
The role of government reimbursement in drug shortages
A Yurukoglu, E Liebman, DB Ridley
American Economic Journal: Economic Policy 9 (2), 348-82, 2017
282017
Drugs and vaccines for developing countries
A Towse, E Keuffel, HE Kettler, DB Ridley
The Oxford handbook of the economics of the biopharmaceutical industry, 302-310, 2012
232012
Retail zoning and competition
DB Ridley, FA Sloan, Y Song
Working Paper, 2010
222010
No shot: US vaccine prices and shortages
DB Ridley, X Bei, EB Liebman
Health Affairs 35 (2), 235-241, 2016
212016
Priorities for the priority review voucher
DB Ridley
The American journal of tropical medicine and hygiene 96 (1), 14, 2017
192017
The cost of inefficiency in US hospitals, 1985-1997.
BR Shah, SD Reed, J Francis, DB Ridley, KA Schulman
Journal of Health Care Finance 30 (1), 1-9, 2003
182003
Strategic interaction among governments in the provision of a global public good
MK Kyle, DB Ridley, S Zhang
Journal of Public Economics 156, 185-199, 2017
162017
Priority review vouchers to encourage innovation for neglected diseases
HG Grabowski, DB Ridley, JL Moe
Prescribing cultures and pharmaceutical policy in the Asia-Pacific, 2009
162009
Spending on postapproval drug safety
DB Ridley, JM Kramer, HH Tilson, HG Grabowski, KA Schulman
Health Affairs 25 (2), 429-436, 2006
162006
Forecasting market share in the US pharmaceutical market
S Regnier, DB Ridley
nature reviews drug discovery 14 (9), 594-595, 2015
142015
The system can't perform the operation now. Try again later.
Articles 1–20